# Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

> **NCT03553823** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Chronic Plaque-type Psoriasis

## Interventions

- **PROCEDURE:** Skin biopsies

## Key facts

- **NCT ID:** NCT03553823
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-14
- **Primary completion:** 2020-01-28
- **Final completion:** 2020-01-28
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03553823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03553823, "Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03553823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*